ProCE Banner Activity

CME

From Biomarkers to Treatment: The New Need-to-Know in Early Breast Cancer

Multimedia
In this on-demand webcast from a live symposium, experts Heather McArthur, MD, MPH; Jennifer K. Litton, MD; and Rita Nanda, MD discuss the most up-to-date guidance on managing early-stage breast cancer.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 08, 2022

Expiration: June 07, 2023

No longer available for credit.

Share

Faculty

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Jennifer K. Litton

Jennifer K. Litton, MD

Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Rita Nanda

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for medical oncologists, pathologists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guidelines and expert recommendations for germline BRCA testing in patients with early-stage breast cancer
  • Develop genetic testing and risk assessment strategies that incorporate expert guidance to identify all patient subgroups with EBC at high risk for recurrence
  • Discuss with patients how their risk of progression affects prognosis and therapeutic planning
  • Identify patients with EBC most likely to benefit from recently approved neoadjuvant/adjuvant targeted or immunotherapy agents
  • Plan adjuvant therapy using PARP inhibitor, immune checkpoint inhibitor, and/or CDK4/6 inhibitors for select patients with EBC
  • Manage treatment-related adverse events in the early-stage breast cancer setting associated with new treatment options to improve adherence, improve patient experience, and optimize outcomes

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH, has disclosed that she has served on advisory boards for AstraZeneca, Bristol-Myers Squibb, Crown Bioscience, Daiichi Sankyo, Gilead Sciences, Immunomedics, Lilly, Merck, Pfizer, Puma Biotech, and Seattle Genetics and has received funds for research support paid to her institution from Bristol-Myers Squibb and Merck.

Faculty Disclosure

Primary Author

Jennifer K. Litton, MD

Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jennifer K. Litton, MD, has disclosed that she has received funds for research support from AstraZeneca, EMD-Serono, Genentech, Merck, Pfizer, and Zenith.

Rita Nanda, MD

Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Rita Nanda, MD, has disclosed that she has received funds for research support from Arvinas, AstraZeneca, Celegent, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, Seattle Genetics, and Taiho and has served on advisory boards for AstraZeneca, BeyondSpring, Cardinal Health, Fuji Film, Immunomedics/Gilead Infinity, iTeos, MacroGenics, Merck, OBI, OncoSec, and Seattle Genetics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Jill A. Sakai,

Contributing Editor

Jill Sakai, PhD has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 08, 2022, through June 07, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for early-stage breast cancer.